ENDRA Life Sciences (NASDAQ:NDRA) Stock Jumps 1.9% – Here’s What Happened

ENDRA Life Sciences Inc. (NASDAQ:NDRA) was up 1.9% during trading on Friday. The stock traded as high as $6.32 and last traded at $6.04. 37,386 shares changed hands during trading, a decline of 40% from the average daily volume of 62,664 shares. The stock had previously closed at $5.93.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Weiss Ratings raised shares of ENDRA Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 10th. Ascendiant Capital Markets cut their price target on shares of ENDRA Life Sciences from $27.00 to $25.00 and set a “buy” rating for the company in a research note on Monday, June 1st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, ENDRA Life Sciences currently has a consensus rating of “Hold” and a consensus price target of $25.00.

ENDRA Life Sciences Stock Up 1.9%

The stock has a 50-day simple moving average of $5.14 and a two-hundred day simple moving average of $4.95. The firm has a market cap of $9.06 million, a PE ratio of -0.95 and a beta of -0.05.

ENDRA Life Sciences (NASDAQ:NDRA) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.21. Research analysts expect that ENDRA Life Sciences Inc. will post -4.11 earnings per share for the current year.

Institutional Investors Weigh In On ENDRA Life Sciences

A hedge fund recently bought a new stake in ENDRA Life Sciences stock. Citizens Financial Group Inc. RI bought a new stake in shares of ENDRA Life Sciences Inc. (NASDAQ:NDRA) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 28,400 shares of the company’s stock, valued at approximately $151,000. Citizens Financial Group Inc. RI owned about 2.24% of ENDRA Life Sciences as of its most recent filing with the Securities and Exchange Commission. 1.19% of the stock is currently owned by institutional investors and hedge funds.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences Inc is a medical technology company developing noninvasive imaging solutions for the assessment of tissue properties. Its technology is designed to expand the capabilities of conventional ultrasound systems by providing quantitative information that may support the detection and monitoring of disease.

The company’s lead platform, TAEUS (Thermo-Acoustic Enhanced UltraSound), is being developed initially for the evaluation of liver fat associated with metabolic dysfunction-associated steatotic liver disease and related conditions.